

U.S. Appln. S.N. 10/534,988
AMENDMENT

PATENT

IN THE CLAIMS:

Please cancel claims 11-15, 18 and 23-27, amend claims 16, 17 and 19, and add new claim 28, as shown below in the detailed listing of all claims which are, or were, in the application:

Claims 1-15 (canceled).

16. (Currently amended) A method for treatment or prevention of a disease or disorder characterized by local inflammatory reaction curable by immunosuppression, comprising

administering to a person or animal in need thereof a pharmaceutical composition comprising a pharmaceutically acceptable agent or salt thereof capable of acidifying cell cytoplasm,

wherein an effective amount of said agent is administered in an essentially non-dissociated form to said person or animal, and

wherein said agent is mixed with a carrier to adjust the pH of said composition to a pH range of 6.1 to 7.0.

17. (Currently amended) The method of claim 16, wherein the disease or disorder is a member of the group consisting of a local

U.S. Appln. S.N. 10/534,988
AMENDMENT

PATENT

inflammatory disease, ~~a systemic inflammatory disease~~, an autoimmune disease and an allergic condition.

18. (Canceled)

19. (Currently amended) The method of ~~claim 18~~ claim 17, wherein said reaction involves activation of cells of innate immune system.

20. (Previously presented) The method of claim 19, wherein said reaction is a member of the group consisting of contact hypersensitivity reactions, delayed type hypersensitivity reactions, acute graft rejection, psoriasis, dermatitis, periodontitis, mastitis, and vasculitis.

21. (Previously presented) The method of claim 16, wherein the agent is administered systemically or locally.

22. (Previously presented) The method of claim 21, where said agent is administered topically.

Claims 23-27 (Canceled).

U.S. Appln. S.N. 10/534,988
AMENDMENT

PATENT

28. (New) The method according to claim 16, wherein the agent is
cis-urocanic acid.